Robert A Klug Net Worth

The estimated Net Worth of Robert A Klug is at least $719 mil dollars as of 23 February 2018. Robert Klug owns over 1,157 units of Quest Diagnostics stock worth over $599,345 and over the last 9 years Robert sold DGX stock worth over $119,935.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Robert Klug DGX stock SEC Form 4 insiders trading

Robert has made over 1 trades of the Quest Diagnostics stock since 2018, according to the Form 4 filled with the SEC. Most recently Robert sold 1,157 units of DGX stock worth $119,935 on 23 February 2018.

The largest trade Robert's ever made was selling 1,157 units of Quest Diagnostics stock on 23 February 2018 worth over $119,935. On average, Robert trades about 41 units every 0 days since 2015. As of 23 February 2018 Robert still owns at least 3,903 units of Quest Diagnostics stock.

You can see the complete history of Robert Klug stock trades at the bottom of the page.

What's Robert Klug's mailing address?

Robert's mailing address filed with the SEC is C/O QUEST DIAGNOSTICS INCORPORATED, 3 GIRALDA FARMS, MADISON, NJ, 07940.

Insiders trading at Quest Diagnostics

Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty y Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.

What does Quest Diagnostics do?

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator

Complete history of Robert Klug stock trades at Quest Diagnostics

Quest Diagnostics executives and stock owners

Quest Diagnostics executives and other stock owners filed with the SEC include:

• Stephen Rusckowski,
  Chairman of the Board, President, Chief Executive Officer
• Manuel Mendez,
  Executive Officer
• Stephen H. Rusckowski,
  Chairman, Pres & CEO
• Mark Guinan,
  Chief Financial Officer, Executive Vice President
• James Davis,
  Executive Vice President, General Diagnostics
• Carrie Manner,
  Senior Vice President - Advanced Diagnostics
• Catherine Doherty,
  Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing
• Michael Prevoznik,
  Senior Vice President, General Counsel
• James E. Davis,
  Exec. VP of Gen. Diagnostics
• Carrie Eglinton Manner,
  Sr. VP of Advanced Diagnostics
• Daniel Stanzione,
  Lead Independent Director
• Gary Pfeiffer,
  Independent Director
• Denise Morrison,
  Independent Director
• Gail Wilensky,
  Independent Director
• Timothy Main,
  Independent Director
• Timothy Ring,
  Independent Director
• Vicky Gregg,
  Independent Director
• Helen Torley,
  Independent Director
• Wright Lassiter,
  Independent Director
• Michael E. Prevoznik,
  Sr. VP & Gen. Counsel
• Mark J. Guinan,
  Exec. VP & CFO
• Gary D. Samuels,
  VP of Corp. Communications
• Timothy Sharpe,
  VP of Compliance
• Shawn C. Bevec,
  VP of Investor Relation
• Gabrielle Wolfson,
  Sr. VP and Chief Information & Digital Officer
• Michael J. Deppe,
  VP, Corp. Controller & Chief Accounting Officer
• Robert B Carter,
  Director
• Jeffrey M Leiden,
  Director
• Jenne K Britell,
  Director
• Robert A Klug,
  VP, Corporate Controller
• Everett Cunningham,
  SVP, Commercial
• John B Ziegler,
  Director
• Jon R Cohen,
  SVP and Chief Medical Officer
• William F Buehler,
  Director
• John B. Haydon,
  SVP, Operations
• Kathy Ordonez,
  SVP, Discovery & Development
• Robert Hagemann,
  Corp VP & Chief Fin Officer
• Surya N Mohapatra,
  President & COO
• Joan Elizabeth Miller,
  Sr VP -Pathology& HospServices
• John C Md Baldwin,
  Director
• Wayne R. Simmons,
  Vice President, Operations
• Rosanne Haggerty,
  Director
• Plc Gsk,
  10% owner
• Thomas W Ii Grant,
  Executive Officers
• William R Grant,
  Director
• Thomas F Bongiorno,
  Vice President and Controller
• James F Iii Flaherty,
  Director
• David M Zewe,
  Sr. VP -Diagnostic Testg Ops
• Robert E Peters,
  Vice President, Sales & Mktg.
• Kenneth W/Nj Freeman,
  Chairman, Chief Exec Officer
• Mary A Cirillo,
  Director
• Kenneth D Brody,
  Director
• Gerald C Marrone,
  Sr. VP, Administration
• Luis Diaz,
  Director
• Tracey Doi,
  Director
• Michael J Deppe,
  SVP, Corp. Controller & CAO
• Sam Samad,
  Executive Vice President & CFO
• Patrick Plewman,
  SVP for Diagnostic Services
• Karthik Kuppusamy,
  SVP, Clinical Solutions
• J. E. Davis,
  CEO and President
• Mark E Delaney,
  SVP & Chief Commercial Officer
• Mark A Gardner,
  SVP of Molecular Gen & Oncol